FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297219> ?p ?o ?g. }

• W4286297219 endingPage "TPS4177" @default.
• W4286297219 startingPage "TPS4177" @default.
• W4286297219 abstract "TPS4177 Background: The anti–PD-L1 antibody atezolizumab (ATEZO) prevents PD-L1 from interacting with PD-1 and B7.1, thus reinvigorating antitumor T cell activity. Anti-VEGF bevacizumab (BEV) increases dendritic cell maturation, enhances T cell infiltration, and reduces myeloid-derived suppressor cells and regulatory T cells in tumors. ATEZO + BEV is FDA approved for first-line treatment of advanced HCC based on the IMbrave 150 study. Locoregional radiotherapy (e.g., Y90 TARE) enhances the diversity of the intratumoral T cell receptor repertoire and increases tumor antigen release. We hypothesize that the Y90 TARE + BEV + ATEZO combination induces synergistic tumor killing and prolongs progression-free survival in patients (pts) receiving Y90 TARE (HR = 0.6 when compared to Y-90 TARE alone). Methods: Eligible pts have HCC that cannot be surgically resected (confirmed by pathology review), is at least BCLC stage B, and is outside Milan criteria. Other requirements include ECOG PS of 0-1 at screening, measurable disease by RECIST 1.1, no prior systemic therapy, and FLR estimated at ≥ 40% post local therapy. Pts must have a pretreatment liver biopsy taken and then be randomized 1:1 to TARE (Arm A) or TARE + ATEZO + BEV (Arm B). Pts will have TARE mapping followed by TARE treatment. In Arm B, pts will begin TARE treatment followed by BEV + ATEZO (4 wks [± 1 wk] later). Pts will have abdominal MRI or CT scans every 12 weeks and CT scans of the chest every 24 wks. The primary study objective is to assess and compare pts' progression-free survival (per mRECIST 1.1) in each study arm. The main secondary objective is to determine the safety and tolerability (CTCAE v5) of pts in Arm B. Exploratory objectives are to define the use of cellular and circulating biomarkers in the prediction of improved clinical outcomes of pts in Arm B. Symptoms experienced by pts in both arms using patient-reported outcomes will be assessed. Disease progression will be captured by both RECIST 1.1 and mRECIST. We plan to assess the safety of Y90 TARE + BEV + ATEZO in the first 10 pts randomized to Arm B for two cycles, and if there are no grade ≥ 3 unexpected toxicities possibly, probably, or definitely related to combined TARE + BEV + ATEZO, continue to accrue 128 pts in total (current enrollment n- = 5). Pts will continue study treatment (Arm B) for a total of 24 months from initiation of TARE or until intolerable toxicity or disease progression occur, whichever is earlier. Enrollment began in September 2020. Clinical trial information: NCT04541173." @default.
• W4286297219 created "2022-07-21" @default.
• W4286297219 creator A5000447730 @default.
• W4286297219 creator A5006169161 @default.
• W4286297219 creator A5006427678 @default.
• W4286297219 creator A5007044838 @default.
• W4286297219 creator A5012936802 @default.
• W4286297219 creator A5017947396 @default.
• W4286297219 creator A5023487474 @default.
• W4286297219 creator A5024332142 @default.
• W4286297219 creator A5028309294 @default.
• W4286297219 creator A5028411727 @default.
• W4286297219 creator A5045096676 @default.
• W4286297219 creator A5045482037 @default.
• W4286297219 creator A5051355971 @default.
• W4286297219 creator A5051500944 @default.
• W4286297219 creator A5055725897 @default.
• W4286297219 creator A5088976086 @default.
• W4286297219 creator A5091196602 @default.
• W4286297219 date "2022-06-01" @default.
• W4286297219 modified "2023-10-18" @default.
• W4286297219 title "An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC)." @default.
• W4286297219 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps4177" @default.
• W4286297219 hasPublicationYear "2022" @default.
• W4286297219 type Work @default.
• W4286297219 citedByCount "0" @default.
• W4286297219 crossrefType "journal-article" @default.
• W4286297219 hasAuthorship W4286297219A5000447730 @default.
• W4286297219 hasAuthorship W4286297219A5006169161 @default.
• W4286297219 hasAuthorship W4286297219A5006427678 @default.
• W4286297219 hasAuthorship W4286297219A5007044838 @default.
• W4286297219 hasAuthorship W4286297219A5012936802 @default.
• W4286297219 hasAuthorship W4286297219A5017947396 @default.
• W4286297219 hasAuthorship W4286297219A5023487474 @default.
• W4286297219 hasAuthorship W4286297219A5024332142 @default.
• W4286297219 hasAuthorship W4286297219A5028309294 @default.
• W4286297219 hasAuthorship W4286297219A5028411727 @default.
• W4286297219 hasAuthorship W4286297219A5045096676 @default.
• W4286297219 hasAuthorship W4286297219A5045482037 @default.
• W4286297219 hasAuthorship W4286297219A5051355971 @default.
• W4286297219 hasAuthorship W4286297219A5051500944 @default.
• W4286297219 hasAuthorship W4286297219A5055725897 @default.
• W4286297219 hasAuthorship W4286297219A5088976086 @default.
• W4286297219 hasAuthorship W4286297219A5091196602 @default.
• W4286297219 hasConcept C121608353 @default.
• W4286297219 hasConcept C126322002 @default.
• W4286297219 hasConcept C143998085 @default.
• W4286297219 hasConcept C2775949291 @default.
• W4286297219 hasConcept C2776694085 @default.
• W4286297219 hasConcept C2777701055 @default.
• W4286297219 hasConcept C2777802072 @default.
• W4286297219 hasConcept C2780030458 @default.
• W4286297219 hasConcept C71924100 @default.
• W4286297219 hasConceptScore W4286297219C121608353 @default.
• W4286297219 hasConceptScore W4286297219C126322002 @default.
• W4286297219 hasConceptScore W4286297219C143998085 @default.
• W4286297219 hasConceptScore W4286297219C2775949291 @default.
• W4286297219 hasConceptScore W4286297219C2776694085 @default.
• W4286297219 hasConceptScore W4286297219C2777701055 @default.
• W4286297219 hasConceptScore W4286297219C2777802072 @default.
• W4286297219 hasConceptScore W4286297219C2780030458 @default.
• W4286297219 hasConceptScore W4286297219C71924100 @default.
• W4286297219 hasIssue "16_suppl" @default.
• W4286297219 hasLocation W42862972191 @default.
• W4286297219 hasOpenAccess W4286297219 @default.
• W4286297219 hasPrimaryLocation W42862972191 @default.
• W4286297219 hasRelatedWork W2892356278 @default.
• W4286297219 hasRelatedWork W2898246178 @default.
• W4286297219 hasRelatedWork W3167888110 @default.
• W4286297219 hasRelatedWork W3204165393 @default.
• W4286297219 hasRelatedWork W3206932502 @default.
• W4286297219 hasRelatedWork W3207330861 @default.
• W4286297219 hasRelatedWork W4220958468 @default.
• W4286297219 hasRelatedWork W4247066646 @default.
• W4286297219 hasRelatedWork W4281630940 @default.
• W4286297219 hasRelatedWork W4304092119 @default.
• W4286297219 hasVolume "40" @default.
• W4286297219 isParatext "false" @default.
• W4286297219 isRetracted "false" @default.
• W4286297219 workType "article" @default.